Botanix News Hub
Welcome to our home for news – the latest headlines, all in one place. Click through to view a selection of our media coverage, industry news, videos and more.
The legal cannabis market in Australia is set to boom, and cannabis is turning out to be the one thing that wouldn’t be hampered by seasonality. The country has one of the largest medicinal cannabis markets that is regulated by the federal government. The cannabis industry is one of the most disputed sectors throughout the world, and over the past few months, significant development has been observed in the industry.
Click HERE to read the article on Kalkine Media.
Amid the difficulties created by the COVID-19 pandemic, synthetic cannabinoid company Botanix Pharmaceuticals (ASX: BOT) unveiled an operational boost in the form of support from the US FDA to fast track its first antibacterial product BTX 1801.
Earlier today, the company announced that the FDA’s Office of Antimicrobial Products had granted BTX 1801 – a treatment to prevent post-surgical infections – what’s known as qualified infectious disease product (QIDP) status which means Botanix can receive a variety of incentives as part of its drug development program.
Click HERE to read the article on SmallCaps.
Botanix Pharmaceuticals Limited (ASX: BOT) today provided investors with an update on its suite of cannabis-derived clinical trials that target dermatological and antimicrobial conditions. In addition to this, the company has provided its roadmap, outlining how Botanix will be moving forward amid the COVID-19 crisis.
Click HERE to read the article on The Green Fund.